Home Categories Send inquiry

OEM manufacturer Rivaroxaban Intermediates - Sorafenib CAS 284461-73-0 Purity ≥99.0% (HPLC) API Factory High Quality – Ruifu

Commercial Supply Sorafenib Tosylate and Related Intermediates:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6

Name Sorafenib
Synonyms Sorafenib Free Base
CAS Number 284461-73-0
CAT Number RF-API04
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C21H16ClF3N4O3
Molecular Weight 464.82
Density 1.454±0.06 g/cm3
Solubility  Soluble in DMSO
Shipping Conditions Ambient Temperature
Brand Ruifu Chemical
Item Specifications
Appearance White to Off-White Powder
Purity / Analysis Method ≥99.0% (HPLC)
Identification H-NMR, MS
Loss on Drying ≤1.0%
Residue on Ignition ≤0.10%
Single Impurity ≤0.20% (HPLC)
Total Impurities  ≤1.0% (HPLC)
Heavy Metals ≤20ppm
Clarity of Solution Conform to Standard
Test Standard Enterprise Standard
Usage RCC & HCC

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Sorafenib Tosylate (CAS: 475207-59-1) is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and HCC. Sorafenib Tosylate (CAS: 475207-59-1) can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth. Sorafenib is an inhibitor of Raf-1 and B-RAF as well as several tyrosine kinases.